Prescription drug savings from Johnson & Johnson

Prescription medications can be a significant financial burden, especially for those who are uninsured or underinsured. Recognizing this challenge, Johnson & Johnson (formerly Janssen Pharmaceuticals) has established the Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF), a nonprofit organization dedicated to providing eligible patients with free prescription medicines.

How the patient assistance program works

The Johnson & Johnson Patient Assistance Program offers access to 35 prescription products for individuals who meet specific eligibility requirements and reside in the United States or a U.S. Territory. Applying for the program is free and requires completing a single application form. Once approved, patients can receive their medications for up to one year, with the possibility of reapplying annually.

Applying for the Johnson & Johnson Patient Assistance Programs

To apply for the Johnson & Johnson Patient Assistance Programs, individuals need to complete a straightforward application form. The application process is free, and applicants only need to submit one application to be considered for multiple medications.

The application form will require applicants to provide personal and financial information. This information is necessary to determine eligibility based on income guidelines and residency requirements. Once the application is submitted, it will be reviewed by the foundation, and applicants will be notified of their eligibility status. Patient Assistance Program Application (jjpaf.org)

Eligibility criteria for the Patient Assistance Program

To determine eligibility for the Johnson & Johnson Patient Assistance Program, certain requirements must be met. While the specific criteria may vary depending on the medication, common factors considered for eligibility include:

Medication requirements

To be eligible for the Johnson & Johnson Patient Assistance Program, patients must have been prescribed medication that is donated by a Johnson & Johnson operating company. This program specifically caters to individuals who require Johnson & Johnson medications for their treatment.

Income Eligibility

Meeting the income requirements is an essential criterion for qualifying for the Patient Assistance Program. Johnson & Johnson has established specific income guidelines that patients must meet to be eligible for free prescription medications. These income requirements may vary depending on the type of medication and the patient’s household size. It is crucial to review the income requirements outlined by Johnson & Johnson to determine if you meet the criteria.

Insurance Coverage

To be eligible for the Johnson & Johnson Patient Assistance Program, enrollees must not have any form of health insurance, including government or private insurance. This program is designed to support individuals who do not have access to insurance coverage for their medications. Patients who have insurance coverage, whether it is through government programs or private providers, may not qualify for the program.

Geographic Eligibility

The Johnson & Johnson Patient Assistance Program is available to individuals residing in the United States or a U.S. Territory. To qualify for this program, patients must provide proof of their residency in the United States or a U.S. Territory. It is important to note that this program is not available to individuals residing outside of the United States or U.S. Territories.

Doctor’s Treatment

To be eligible for the Patient Assistance Program, patients must be under the outpatient care of a U.S.-licensed doctor. This means that the patient’s treatment must be overseen by a doctor who holds a valid license to practice medicine in the United States. Patients receiving inpatient care or treatment from doctors who are not licensed in the United States may not be eligible for the program.

Access to a wide range of medications

The Johnson & Johnson Patient Assistance Programs offer access to a diverse range of prescription medications. With over 35 products available, patients can receive the treatments they need at no cost if they meet eligibility requirements. Below are the drugs available and links to their savings options:

• AKEEGA™ (niraparib and abiraterone acetate) Tablets
• BALVERSA® (erdafitinib) Tablets
• DARZALEX® (daratumumab) Injection for intravenous infusion
• DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) injection for subcutaneous use
• EDURANT® 1 (rilpivirine) Tablets
• ELMIRON® (pentosan polysulfate sodium) Capsules
• ERLEADA® (apalutamide) Tablets
• IMBRUVICA®  (ibrutinib) Capsules/Tablets/Oral Suspension
• Infliximab †Intravenous Infusion
• INVEGA HAFYERA® † (paliperidone palmitate) Extended-Release Injectable Suspension
• INVEGA SUSTENNA® † (paliperidone palmitate) Extended-Release Injectable Suspension
• INVEGA TRINZA® † (paliperidone palmitate) Extended-Release Injectable Suspension
• INVOKAMET® † 1 (canagliflozin/metformin HCI) Tablets
• INVOKAMET® XR † 1 (canagliflozin/metformin HCI) Extended-Release Tablets
• INVOKANA® 1 (canagliflozin) Tablets
• MONOVISC® (high molecular weight hyaluronan) Injection
• OPSUMIT® † (macitentan) Tablets
• ORTHOVISC® (high molecular weight hyaluronan) Injection
• PONVORY™ (ponesimod) Tablets
• PREZCOBIX® 1 (darunavir 800mg/cobicistat 150mg) Tablets
• PREZISTA® 1 (darunavir) Tablets/Oral Suspension
• REMICADE® † (infliximab) IV Infusion
• RISPERDAL CONSTA® † (risperidone) Long-Acting Injection
• RYBREVANT® (amivantamab-vmjw) Injection
• SIMPONI® † (golimumab) Injection
• SIMPONI ARIA® † (golimumab) IV Infusion
• SIRTURO® † (bedaquiline) Tablets
• SPRAVATO® † (esketamine) Nasal Spray, for intranasal use, CIII
• STELARA® (ustekinumab) Injection, for subcutaneous or intravenous use
• SYMTUZA® † (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) Tablets
• TALVEY™ † (talquetamab-tgvs) Injection, for subcutaneous use
• TECVAYLI® † (teclistamab-cqyv) Injection, for subcutaneous use
• TRACLEER® † (bosentan) Tablets
• TREMFYA® (guselkumab) Injection, for subcutaneous use
• UPTRAVI® (selexipag) Tablets
• VELETRI® (epoprostenol) Injection
• XARELTO® † 1 (rivaroxaban) Tablets or Oral Suspension
• YONDELIS® (trabectedin) Injection for intravenous infusion

Companies supporting the Patient Assistance Programs

The Johnson & Johnson Patient Assistance Foundation is made possible through the generosity of several donor drug maker companies within the Johnson & Johnson family. These companies include:

• Actelion Pharmaceuticals US, Inc.
• DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc.
• Janssen Biotech, Inc.
• Janssen Therapeutics, Division of Janssen Products, LP
• Janssen Pharmaceuticals, Inc.

The commitment and support of these companies enable the foundation to provide free prescription medications to eligible patients.

Conclusion

Prescription drug savings programs, such as the Johnson & Johnson Patient Assistance Programs, are invaluable resources for individuals who face financial barriers to accessing necessary medications. By providing free prescription medicines to eligible patients, Johnson & Johnson and its donor companies demonstrate their commitment to improving access to healthcare.

Through these programs, individuals can receive the medications they need to manage their health conditions effectively, without experiencing the additional burden of high costs. The Johnson & Johnson Patient Assistance Programs truly make a difference in the lives of patients and contributes to a more equitable healthcare system.

Sources

• Access & Support – REMICADE® (infliximab) HCP
• AKEEGA™ Paying for – Janssen CarePath